Corrigendum to “Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration” [Ophthalmology Science. 2025;5:100796]
Hemal P. Patel, Cason B. Robbins, Jamie J. Karl, Peter Weng, Lejla Vajzovic, Sharon Fekrat
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinal Diseases and Treatments · Neurological Complications and Syndromes · Cerebral Venous Sinus Thrombosis
The authors of “Oral antithrombotic medication is associated with improved visual outcomes in eyes with submacular hemorrhage from wet age-related macular degeneration” would like to note the following corrections to their article.
In Table 4, the 14th row of the Variables column should read as follows (correction in bold):Table 4. Regression ResultsVariables(1) Difference between Final and Presenting VA(2) Difference between Final and Presenting VA(3) Difference between Final and Presenting VA(4) Difference between Final and Presenting VAOn anticoagulant–0.866∗–0.711∗(0.256)(0.225)On antiplatelet–0.426‡–0.692∗(0.247)(0.194)Male sex0.0373–0.04380.3300.313(0.287)(0.280)(0.256)(0.216)Age–0.00926–0.01650.00883–0.00296(0.0146)(0.0122)(0.0138)(0.00973)Anti-VEGF0.3360.4870.3930.246(0.374)(0.346)(0.325)(0.271)Vitrectomy0.431‡0.3120.155–0.131(0.258)(0.262)(0.255)(0.195)Pneumatic displacement–0.0741–0.218–0.163–1.026∗(0.457)(0.442)(0.497)(0.381)Cataract surgery after SMH–1.101∗–0.924∗–0.431–0.890∗(0.308)(0.300)(0.273)(0.234)Initial VA–0.528∗–0.691∗–0.570∗–0.744∗(0.163)(0.155)(0.163)(0.155)Time to presentation compared with <7 d 7–14 d0.0968∗∗0.02350.05480.0286(0.0490)(0.0442)(0.0498)(0.0373) 15–30 d0.468–0.104–0.0952–0.151(0.340)(0.313)(0.314)(0.229) >30 d0.5370.4730.3360.583(0.409)(0.361)(0.481)(0.451) Time followed–0.139–0.788†–0.0201–0.523†(0.371)(0.371)(0.332)(0.257)SMH size compared with 1–3 DD 4–5 DD1.517∗2.200∗(0.485)(0.335) >5 DD1.451∗1.737∗(0.366)(0.255)SMH thickness (microns)–0.000606–0.000992∗(0.000458)(0.000330)Constant1.0742.187‡–0.2061.780‡(1.340)(1.131)(1.310)(0.990)Number of eyes42306046Number of subjects40295945DD = disc diameter; SMH = submacular hemorrhage; VA = visual acuity.Regression results provided using a multivariate generalized estimating equation model to account for using both eyes of patients with bilateral submacular hemorrhage. Standard errors in parentheses.∗P < 0.01.†P < 0.05.‡P < 0.1
“SMH size compared with 1-3 DD 4-5 DD”
In Supplemental Tables 7 and 8, the first row of the first column under “Difference in Final and Presentation VA” should read as follows (correction in bold):
“On an antiplatelet”